The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.
Timothy Mills, chairman of the board of Taligen, said: “With this additional funding, we expect to move into clinical development with all of our lead candidates.”